CEBPA and acute myeloid leukemia: Targeted sequencing confirmed the prevalence of GATA2 ZnF1 mutations in CEBPA mutant AML, with additional common mutations observed only in a minority (6/35) of patients (Fasan et al., 2013, Greif et al., 2012, Ping et al., 2017).